Key result
Design paper outlines a prospective study evaluating rivaroxaban PK/PD in Chinese NVAF patients.
Why the study?
Few studies have investigated the pharmacokinetics and pharmacodynamics of rivaroxaban in Chinese patients with non-valvular atrial fibrillation to provide a reference for dose selection and individualized therapy.
What are the population pharmacokinetics and pharmacodynamics of rivaroxaban in Chinese patients with non-valvular atrial fibrillation?
Population
Chinese patients with non-valvular atrial fibrillation treated with rivaroxaban
Design
Single-centre prospective study
Follow-up
3 and 6 months
Authors
Loading...
This study protocol outlines a prospective evaluation of the pharmacokinetics and pharmacodynamics of rivaroxaban in Chinese patients with non-valvular atrial fibrillation to guide individualized dosing.
Observational
No
What are the population pharmacokinetics and pharmacodynamics of rivaroxaban in Chinese patients with non-valvular atrial fibrillation?
This study protocol outlines a prospective evaluation of the pharmacokinetics and pharmacodynamics of rivaroxaban in Chinese patients with non-valvular atrial fibrillation to guide individualized dosing.
Liu et al. (2022) conducted an observational in non-valvular atrial fibrillation (NVAF). Rivaroxaban was evaluated on Population pharmacokinetics and pharmacodynamics of rivaroxaban. This rationale and design paper describes a prospective study to evaluate the population pharmacokinetics and pharmacodynamics of rivaroxaban in Chinese patients with non-valvular atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: